View Item 

Show simple item record

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease
dc.contributor.authorFass, R.en_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorZakko, Salam F.en_US
dc.contributor.authorAndhivarothai, N.en_US
dc.contributor.authorPalmers, R. N.en_US
dc.contributor.authorPerez, M. C.en_US
dc.contributor.authorAtkinson, S. N.en_US
dc.date.accessioned2010-06-01T19:19:53Z
dc.date.available2010-06-01T19:19:53Z
dc.date.issued2009-06en_US
dc.identifier.citationFASS, R.; CHEY, W. D.; ZAKKO, S. F.; ANDHIVAROTHAI, N.; PALMER, R. N.; PEREZ, M. C.; ATKINSON, S. N. (2009). "Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease." Alimentary Pharmacology & Therapeutics 29(12): 1261-1272. <http://hdl.handle.net/2027.42/72475>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72475
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19392864&dopt=citationen_US
dc.format.extent283607 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2009 Blackwell Publishing Ltden_US
dc.titleClinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux diseaseen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MIen_US
dc.contributor.affiliationother* Section of Gastroenterology, University of Arizona Health Science Center and Southern Arizona VA Health Care System, Tucson, AZen_US
dc.contributor.affiliationother† Connecticut Gastroenterology Institute at Bristol Hospital, Bristol, CTen_US
dc.contributor.affiliationother§ Research & Development, Takeda Global Research & Development Center, Inc., Deerfield, IL, USAen_US
dc.identifier.pmid19392864en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72475/1/j.1365-2036.2009.04013.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2009.04013.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceDent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710 – 7.en_US
dc.identifier.citedreferenceFass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 79 – 94.en_US
dc.identifier.citedreferenceNojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 473 – 82.en_US
dc.identifier.citedreferenceLocke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc 2003; 58: 661 – 70.en_US
dc.identifier.citedreferenceRobinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 158: 2373 – 6.en_US
dc.identifier.citedreferenceFass R, Ofman JJ. Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901 – 9.en_US
dc.identifier.citedreferenceFass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885 – 92.en_US
dc.identifier.citedreferenceDickman R, Bautista JM, Wong WM, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am J Gastroenterol 2006; 101: 2463 – 9.en_US
dc.identifier.citedreferenceCicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 605 – 13.en_US
dc.identifier.citedreferenceDean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656 – 64.en_US
dc.identifier.citedreferenceKatsuki H, Yagi H, Arimori K, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996; 13: 611 – 5.en_US
dc.identifier.citedreferenceLind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861 – 7.en_US
dc.identifier.citedreferenceKahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249 – 58.en_US
dc.identifier.citedreferenceMetz DC, Vakily M, Dixit T, Mulford D. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 29: 928 – 37.en_US
dc.identifier.citedreferenceVakily M, Zhang W, Wu J, Atkinson S, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25: 627 – 38.en_US
dc.identifier.citedreferenceBate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547 – 55.en_US
dc.identifier.citedreferenceCarlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119 – 24.en_US
dc.identifier.citedreferenceKahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005; 50: 2009 – 18.en_US
dc.identifier.citedreferenceKatz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18: 875 – 82.en_US
dc.identifier.citedreferenceLind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974 – 9.en_US
dc.identifier.citedreferenceRichter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810 – 6.en_US
dc.identifier.citedreferenceWatson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the “sensitive oesophagus”. Gut 1997; 40: 587 – 90.en_US
dc.identifier.citedreferenceChey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23: 69 – 84.en_US
dc.identifier.citedreferenceScholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18: 587 – 94.en_US
dc.identifier.citedreferenceMiner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332 – 9.en_US
dc.identifier.citedreferenceMiner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616 – 20.en_US
dc.identifier.citedreferenceDe La Loge C, Trudeau E, Marquis P, et al. Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol 2004; 2: 778 – 86.en_US
dc.identifier.citedreferenceSharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive esophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from 2 randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731 – 41.en_US
dc.identifier.citedreferenceNexium ®. Esomeprazole Magnesium. Wilmington, DE: AstraZeneca LP, 2008.en_US
dc.identifier.citedreferenceAciphex ®. Rabeprazole Sodium. Tokyo, Japan: Eisai Co., Ltd, 2008.en_US
dc.identifier.citedreferenceDeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190 – 200.en_US
dc.identifier.citedreferenceVakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103: 1906 – 19.en_US
dc.identifier.citedreferenceFreston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999; 20: 195 – 205.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2009.04013.x.pdf
Size:
276.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.